Skip to main content
Menu

Posts tagged with "Diabetes and Obesity"

  • Clinical Trials

    GLP-1 and Obesity

    Let’s have a look at a paper that came out recently in the New England Journal of Medicine. It shows strong results in a therapeutic area that a lot of people have spent a lot of effort on: obesity. I’ve been kicking around the idea of reviewing the history of anti-obesity drug discovery, but it’s… Read More
  • Diabetes and Obesity

    Proteins as Oral Drugs: Possible, But Not Probable

    I have been writing this blog for some time (!) That occurs to me on seeing this article in Nature Reviews Drug Discovery on oral dosing of peptide drugs – I say that because of this 2002 post on the very same subject, at the time directed towards the then-still-somewhat-hot topic of Judah Folkman’s endostatin angiogenesis… Read More
  • Aging and Lifespan

    Metformin and Exercise

    I’ve written about metformin quite a few times over the years on the blog, and for several reasons. It is (for starters) obviously a frontline drug for treatment of Type 2 diabetes, a condition that has unfortunately become more and more common in the world as the world puts on more and more weight. (Side… Read More
  • Biological News

    The Secret Life of the Insulin Receptor

    You’d think that we would understand the workings of something like the insulin receptor by now, wouldn’t you? I worked in the metabolic disease area for several years, and I can give you the canonical version of its activities as it relates to insulin levels and glucose handling out in the canonical tissues (muscle, adipose). Read More
  • Business and Markets

    Zafgen: Will There Be a Third Act?

    A few years ago on this blog, I wrote several times about a small company called Zafgen and their unusual epoxide-based chemical matter (beloranib) that was in development for the rare Prader-Willi syndrome. That’s a genetic disorder that includes, among many other problems, constant hunger (with the complications that you’d expect fro… Read More
  • Biological News

    Exercise And Its Signaling

    It’s a truism among metabolic researchers that if you could find a drug that simulates the effects of exercise you would be very happy with the market for it. But what causes the effects of exercise? That’s one of those simple questions that members of the general public might think that they know the answer… Read More
  • Cancer

    PI3K Inhibitors: You’re Doing It Wrong

    Now here’s an interesting connection between cancer and metabolism, with what look to be direct implications for therapy. A large research team (mostly working out of Weill Cornell) reports some new and important details about PI3K inhibitors, a class of kinase inhibitors that has seen a very large amount of development work indeed. I’v… Read More
  • Biological News

    Type 2 Diabetes May Be a Protein Misfolding Disease

    Here’s a paper that will not calm anyone down about the possibility of prion-like diseases. Those, as many will know, are spread by misfolded proteins that, on contact, template others to follow their example. I last wrote about this field a couple of years ago, when examples appeared of transmissable amyloid pathology in humans, spread… Read More
  • Cardiovascular Disease

    AMPK: Time To Think Hard

    AMP-activated protein kinase, now that’s an enzyme for you. It sits at the center of a cell’s metabolic switchboard, and if you’re talking about anything to do with the response to levels of fuel like glucose or fatty acids and determination of their downstream fates, then AMPK is almost certainly crucial. Activating the enzyme se… Read More
  • Cardiovascular Disease

    Two Diabetes Drug Mysteries

    Here are some data to file under “Drugs do things that we don’t expect”. The SGLT-2 inhibitors are a class of diabetes medications that work by inhibiting the sodium/glucose transporter 2 protein in the kidneys. That keeps glucose from being reabsorbed there; instead, more of it is removed in the urine, and that lowers circulating… Read More